Phase-III clinical trials of Molnupiravir capsules have been initiated to assess its efficacy in treating patients with mild Covid-19 said on Friday Natco Pharma. The first dose under the phase-III trials was given to a patient in the city-based Yashoda Hospitals, said the Hyderabad-based firm.
“Phase-III clinical trial is initiated to evaluate the efficacy and safety of Molnupiravir capsules in mild Covid-19 patients,” Natco Pharma said in a regulatory filing.
Across the country, the clinical trial is planned in 32 hospitals. Molnupiravir has broad anti-influenza activity showed the pre-clinical data, including including highly potent inhibition of SARS-CoV-2 replication, said the drug firm.
It added patients treated with Molnupiravir achieved response within five days of therapy, indicating that the duration of treatment with the drug is short, with the additional advantage of it being an oral therapy.
India has been badly hit by the second wave of coronavirus infections, and hospitals in several states are reeling under a shortage of vaccines, oxygen, drugs and equipment.
With 2,57,299 new coronavirus infections being reported in a day, India’s tally of Covid-19 cases climbed to 2,62,89,290 while the daily deaths were recorded below 4,194 after four days, taking the toll to 2,95,525, according to the Union health ministry data updated on Thursday.